News Release 

Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers

While estrogen receptor - + breast cancers express high levels of three anti-apoptotic Bcl-2 family members, pharmacological inhibition of Bcl-2 and/or Bcl-xL fails to induce cell death in ER + breast cancer cell lines, due to rapid and robust Mcl-1...

Impact Journals LLC

IMAGE

IMAGE: Pharmacological inhibition of Bcl-2 and/or Bcl-xL increases Mcl-1 expression through cap-dependent translation. (A) Relative MCL1 transcript levels were determined by RT-qPCR after treatment with 1.0 μM ABT-263 for 16 hrs.... view more 

Credit: Correspondence to - Rebecca S. Cook - Rebecca.cook@vanderbilt.edu

While estrogen receptor - + breast cancers express high levels of three anti-apoptotic Bcl-2 family members, pharmacological inhibition of Bcl-2 and/or Bcl-xL fails to induce cell death in ER + breast cancer cell lines, due to rapid and robust Mcl-1 upregulation.

Cells treated with a pharmacological inhibitor of cap-dependent translation, or with the mTORC1 inhibitor RAD001/everolimus, displayed reduced protein levels of Mcl-1 under basal conditions, and failed to upregulate Mcl-1 protein expression following treatment with ABT-263, a pharmacological inhibitor of Bcl-2 and Bcl-xL.

Dr. Rebecca S. Cook from Vanderbilt University, in Nashville TN, USA said, "The breast epithelium undergoes many dynamic changes throughout a woman's lifetime."

Specifically, anti-apoptotic Bcl-2 proteins either 1) bind to Bcl-2 effectors to block pore formation in the outer mitochondrial membrane caused by Bak/Bax oligomerization, or 2) sequester Bcl-2 activators, which facilitate Bak/Bax oligomerization.

Estrogen Receptor - positive breast cancer represents 60-70% of all breast cancers diagnosed.

Notably, up to 70% of ER+ breast cancers express Bcl-2, although Bcl-2 is expressed at low levels in other breast cancer subtypes.

In contrast, Bcl-xL and Mcl-1 are widely expressed in ER+ breast cancers, as well as in HER2-amplified and triple negative breast cancers, both in pre-malignant lesions and in high grade tumors.

Similarly, studies in pre-clinical models of ER + breast cancers showed that ABT-263 was ineffective as a single agent, in large part due to rapid Mcl-1 upregulation, although the molecular mechanism driving compensatory Mcl-1 upregulation in response to Bcl-2/Bcl-xL inhibition in ER+ breast cancers are not yet clearly defined.

The Cook research team concluded, "Importantly, we have tested the Mcl-1 selective inhibitor VU661013 in ER+ breast cancer cells, finding that Mcl-1 inhibition increases apoptosis and decreases tumor cell death, particularly when used in combination with ABT-263."

###

Full text - https://doi.org/10.18632/oncotarget.27070

Correspondence to - Rebecca S. Cook - Rebecca.cook@vanderbilt.edu

Keywords - Mcl-1, ABT-263 resistance, mTORC1 signaling, luminal breast cancers

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit http://www.oncotarget.com or connect with @OncotargetJrnl

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
18009220957x105
MEDIA@IMPACTJOURNALS.COM

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.